(Q36189795)

12 August 2017

The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country (English)

1 reference

12 August 2017

gross domestic product

0 references

1 reference

1 reference

Jan Hendrik Richardus

5

object named as

Jan Hendrik Richardus

1 reference

12 August 2017

Mehlika Toy

1

1 reference

12 August 2017

Fatih Oguz Onder

2

1 reference

12 August 2017

Ramazan Idilman

3

1 reference

12 August 2017

Gokhan Kabacam

4

1 reference

12 August 2017

Mithat Bozdayi

6

1 reference

12 August 2017

Meral Akdogan

7

1 reference

12 August 2017

Zarife Kuloglu

8

1 reference

12 August 2017

Aydan Kansu

9

1 reference

12 August 2017

Solko Schalm

10

1 reference

12 August 2017

Cihan Yurdaydin

11

1 reference

12 August 2017

20 July 2012

1 reference

The European Journal of Health Economics

12 August 2017

1 reference

12 August 2017

13

1 reference

12 August 2017

5

1 reference

12 August 2017

663-676

1 reference

Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Chronic hepatitis B: update 2009

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Living donor liver transplantation for hepatitis B cirrhosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

2 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Potency of tenofovir in chronic hepatitis B: mono or combination therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427846

Hepatocellular Carcinoma (HCC)

22 September 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0413-8

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

21 January 2018

1 reference

12 December 2020

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

12 December 2020

Rates and probabilities in economic modelling: transformation, translation and appropriate application

1 reference

12 December 2020

Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil

1 reference

12 December 2020

Chronic hepatitis B. A guideline to diagnosis, approach, management, and follow-up 2007. Turkish Association for the Study of Liver

1 reference

12 December 2020

Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited

1 reference

12 December 2020

10.1007/S10198-012-0413-8

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22815098

1 reference